Michael P DiGiovanna MD, PhD

Associate Professor of Medicine (Medical Oncology) and of Pharmacology

Departments & Organizations

Yale Combined Program in the Biological and Biomedical Sciences (BBS): Molecular Cell Biology, Genetics and Development | Molecular Medicine, Pharmacology, and Physiology

Yale Medical Group

Office of Education: LCME Academic Environment Subcommittee

Office of Student ResearchCancer Center, Yale: Breast Cancer Program; Signal TransductionPharmacologyMedical OncologySignal Transduction

Research Interests

Breast cancer; HER-2/neu/ErbB-2; IGF1 receptor; EGF receptor; Growth factor receptor tyrosine protein kinases in malignancy; Estrogen receptor; Signal transduction; Breast cancer clinical trials more...


  • M.D., Yale University, 1990
  • Ph.D., Yale University, 1990

Selected Publications

  • Koay, D.C, Zerillo, C., Narayan, M., Harris, L.N. and DiGiovanna, M.P., “Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations”, Breast Cancer Research, 12:R62 [Epub ahead of print], 2010
  • Chakraborty, A.K., Welsh, A., and DiGiovanna, M.P., “Co-Targeting IGF1R enhances growth-inhibitory and pro-apoptotic effects of antiestrogens in human breast cancer cell lines”, Breast Cancer Research and Treatment, DOI: 10.1007/s10549-009-0382-5 (2009), 120:327, 2010
  • Chakraborty, A.K. Liang, K. and DiGiovanna, M.P., “Co-Targeting insulin-like growth factor I receptor and HER2: Dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer”, Cancer Research, 68:1538-1545, 2008



Latest News


Edit Profile